Daytime Systolic Ambulatory Blood Pressure With a Direct Switch Between Candesartan Monotherapy and the Fixed‐Dose Combination Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL‐1). Issue 11 (16th September 2013)

• Record Type: Journal Article
• Authors: Zemmrich, Claudia; Lüders, Stephan; Gansz, Andrea; Sturm, Claus‐Dieter; Fimmers, Rolf; Nadal, Jennifer; Schmieder, Roland E.; Schrader, Joachim; Bramlage, Peter
• Is Part Of: Journal of clinical hypertension. Volume 15:Issue 11(2013:Nov.)
• Page Start: 815
• Page End: 819
• Publication Date: 2013-09-16
• Subjects: Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.12202
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract : A direct switch of candesartan to the fixed‐dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling. An open‐label, prospective, single‐arm phase IIIb study was performed in patients with 32 mg candesartan followed by olmesartan/amlodipine 40/10 mg. The primary endpoint was change in mean daytime systolic blood pressure (BP). Mean daytime systolic BP was reduced by 9.2±12.6 mm Hg ( P <.0001) after substituting candesartan for olmesartan/amlodipine (baseline BP 140.2±9.7 mm Hg). The reduction in office BP was 9.4±18.4/4.0±9.6 mm Hg; P <.002). Overall, 61.3% of patients achieved a target BP <140/90 mm Hg using office BP and <135/85 mm Hg using ambulatory BP measurement. There were 8 adverse events with a possible relation to study drug and 1 unrelated serious adverse events. In conclusion, patients with uncontrolled moderate arterial hypertension being treated using candesartan monotherapy achieve a further reduction of BP when switched directly to a fixed‐dose combination of olmesartan 40 mg/amlodipine 10 mg.